Cargando…

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure

Detalles Bibliográficos
Autores principales:	Enriquez, Virginia, Cruz, Judith, Gutierrez, Olga, Salles, Maria Teresa, Vargas, Pablo, Martínez, Arturo, Candelaria, Myrna, Hurtado, Rafael, Cervera, Eduardo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1796587/ http://dx.doi.org/10.1186/1471-2407-7-S1-A41

Ejemplares similares

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
por: Harrach, S, et al.
Publicado: (2016)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
por: McLigeyo, Angela, et al.
Publicado: (2020)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy()
por: Aliano, Stefania, et al.
Publicado: (2013)

Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo
por: Li, Hui, et al.
Publicado: (2016)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
por: Haaß, Wiltrud, et al.
Publicado: (2015)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients
por: Mohajeri, Ehsan, et al.
Publicado: (2015)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
por: Aceves-Luquero, Clara I., et al.
Publicado: (2009)

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
por: Azad, Niyaz A, et al.
Publicado: (2018)

Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
por: Valent, Peter
Publicado: (2007)

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3
por: Wang, Houcai, et al.
Publicado: (2016)

Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib
por: Jin, Yanli, et al.
Publicado: (2016)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
por: Millot, Frédéric, et al.
Publicado: (2021)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
por: Hamza, Marwa S, et al.
Publicado: (2022)

Acute generalized exanthematous pustulosis from imatinib
por: Fu, Lisa W, et al.
Publicado: (2014)

α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2011)

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target
por: Toman, O., et al.
Publicado: (2016)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells
por: Zeng, Chengwu, et al.
Publicado: (2018)

CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML
por: Zhong, An-Ni, et al.
Publicado: (2021)

Tamoxifen-associated vasculitis in a breast cancer patient
por: Candelaria, Myrna, et al.
Publicado: (2007)

Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors
por: Varela, Ignacio, et al.
Publicado: (2017)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells
por: Yang, Hao, et al.
Publicado: (2014)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB
por: Zhu, Xunxun, et al.
Publicado: (2022)

PB1898: BONE MARROW APLASIA – A RARE COMPLICATION OF IMATINIB THERAPY IN CML PATIENTS: ABOUT A CASE
por: chawad, W., et al.
Publicado: (2022)

Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
por: Al-Amleh, Esraa K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f3qe2m11apkcjjptmr6cepa13i